4/14
07:04 pm
tlx
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Neutral
Report
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
4/14
06:50 pm
tlx
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Medium
Report
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
4/14
06:41 pm
tlx
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
Medium
Report
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
4/14
06:35 pm
tlx
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
Medium
Report
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
4/14
04:34 am
tlx
Telix Refinances Convertible Bonds
Low
Report
Telix Refinances Convertible Bonds
4/14
04:32 am
tlx
Telix Refinances Convertible Bonds
Low
Report
Telix Refinances Convertible Bonds
4/13
08:34 am
tlx
Telix Pharmaceuticals (TLX) had its "outperform" rating reaffirmed by Wedbush. They now have a $22.00 price target on the stock.
Low
Report
Telix Pharmaceuticals (TLX) had its "outperform" rating reaffirmed by Wedbush. They now have a $22.00 price target on the stock.
4/13
08:00 am
tlx
Telix Pharmaceuticals (TLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Neutral
Report
Telix Pharmaceuticals (TLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
4/13
06:30 am
tlx
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Low
Report
Telix and Regeneron Announce Strategic Radiopharma Collaboration
4/11
01:00 am
tlx
High
Report
4/9
06:51 pm
tlx
FDA Accepts NDA for TLX101-Px (Pixclara®)
Medium
Report
FDA Accepts NDA for TLX101-Px (Pixclara®)
4/9
06:50 pm
tlx
FDA Accepts NDA for TLX101-Px (Pixclara®)
Medium
Report
FDA Accepts NDA for TLX101-Px (Pixclara®)
4/8
06:58 pm
tlx
Telix Strengthens Board with Additional Director Appointments
Low
Report
Telix Strengthens Board with Additional Director Appointments
4/8
06:44 pm
tlx
Telix Strengthens Board with Additional Director Appointments
Low
Report
Telix Strengthens Board with Additional Director Appointments
4/7
08:55 am
tlx
Telix Pharmaceuticals (TLX) had its "outperform" rating reaffirmed by Wedbush. They now have a $22.00 price target on the stock.
Low
Report
Telix Pharmaceuticals (TLX) had its "outperform" rating reaffirmed by Wedbush. They now have a $22.00 price target on the stock.
4/7
08:02 am
tlx
Telix Pharmaceuticals (TLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Telix Pharmaceuticals (TLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
4/6
07:37 pm
tlx
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Medium
Report
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
4/6
06:57 pm
tlx
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Medium
Report
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
4/1
07:53 pm
tlx
Telix Appoints David Gill as Non-Executive Director
Low
Report
Telix Appoints David Gill as Non-Executive Director
4/1
06:59 pm
tlx
Telix Appoints David Gill as Non-Executive Director
Low
Report
Telix Appoints David Gill as Non-Executive Director
3/15
05:26 pm
tlx
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Low
Report
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
3/15
05:25 pm
tlx
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Low
Report
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
3/15
01:05 am
tlx
Low
Report
3/9
07:19 pm
tlx
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Low
Report
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
3/9
06:34 pm
tlx
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Medium
Report
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives